Business
Announcement on Voluntary Disclosure of the Completion of the First Subject Enrollment in Phase III Clinical Trial of FDA018 Antibody-drug Conjugate for the Treatment of Triple-negative Breast Cancer
Announcement on Voluntary Disclosure of the Completion of the First Subject Enrollment in Phase III Clinical Trial of FDA018 Antibody-drug Conjugate for the Treatment of Triple-negative Breast Cancer
About this update from Shanghai Fudan Zhangjiang Bio Pharmaceutical Co. Ltd. Class A
Announcement on Voluntary Disclosure of the Completion of the First Subject Enrollment in Phase III Clinical Trial of FDA018 Antibody-drug Conjugate for the Treatment of Triple-negative Breast CancerThe abstract is for reference only. Please refer to the full text of the announcement on the very day.Link of Full Text for Reference: View Attachment